APT-101 Reduces Fibrosis, Inflammation in Mouse Model |... - Scleroderma News
8/9/2022 12:00:00 AM2 years 8 months ago
by Lindsey Shapiro, PhD, Lindsey Shapiro, PhD
by Lindsey Shapiro, PhD, Lindsey Shapiro, PhD
In a mouse model of scleroderma with interstitial lung disease, APT-101 reduced symptoms of fibrosis, inflammation, and cell death.
The investigational oral therapy APT-101 was well tolerated and reduced fibrosis, or scarring, in a mouse model of systemic sclerosis (SSc), according to a recent presentation from the therapy’s deve… [+3610 chars]
full article...